SKSujin Kang

Sujin Kang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sujin Kang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Outcomes and Factors Associated With Cenegermin Response in Neurotrophic Keratopathy

    by Sujin Kang, Margaret Y. Wang, Arjun Sharma, Andrew Rong, Angela Y. Zhu

    Purpose: To evaluate real-world clinical outcomes after topical cenegermin therapy for neurotrophic keratopathy (NK) and identify demographic and clinical factors associated with treatment nonresponse. Methods: This retrospective clinical cohort study included adults with NK treated with at least one 8-week course of topical cenegermin 0.002% (Oxervate) at a tertiary referral center between March 2019 and March 2024. Clinical response was assessed at the follow-up visit closest to 8 weeks after treatment initiation and categorized as improved or not improved. Demographic characteristics, NK etiology, Mackie stage, baseline visual acuity, prior treatments, and treatment timing were analyzed. Multivariable logistic regression was used to identify factors associated with nonresponse, and Kaplan–Meier analysis evaluated freedom from corneal deterioration. Results: A total of 107 eyes from 107 patients were included. After 1 treatment cycle, 59 eyes (55.1%) demonstrated clinical improvement and 48 eyes (44.9%) did not improve. On multivariable analysis, older age was associated with higher odds of nonresponse (adjusted odds ratio [OR] 1.35 per decade; 95% confidence interval [CI] 1.01 to 1.80; P = 0.040), as was male sex (adjusted OR 2.52; 95% CI 1.03–6.19; P = 0.044). Mackie stage 2 to 3 disease at treatment initiation was associated with lower odds of nonresponse compared with stage 1 disease (adjusted OR 0.33; 95% CI 0.11–0.95; P = 0.041). During follow-up, 28 eyes (26.2%) developed corneal deterioration. Conclusions: Clinical response to cenegermin in NK was heterogeneous. Older age and male sex were exploratory predictors of nonresponse, whereas more advanced Mackie stage showed greater short-term improvement but lower durability, supporting individualized counseling and posttreatment monitoring.

  • Open Access

    Morgagnian Cataract: Clinical Features, Surgical Management, and Outcomes

    by Sujin Kang, Ryan T. Wallace, Steven J. Gedde, Caroline M. Borie, Zubair A. Ansari, Luis E. Vazquez, Anat Galor, Basil K. Williams, Sonia H. Yoo, Despoina Theotoka

  • Open Access

    Recurrent Corneal Erosion Syndrome in Epithelial Basement Membrane Dystrophy: Current Treatments and Mechanism-Guided Therapeutic Opportunities

    by Sujin Kang, Alfonso L. Sabater, Sotiria Palioura, Sonia H. Yoo

    Recurrent corneal erosion syndrome (RCES) and epithelial basement membrane dystrophy (EBMD), also termed anterior basement membrane dystrophy, are distinct entities. RCES most often follows shearing corneal trauma, whereas EBMD may be asymptomatic, may blur vision without pain, or may predispose to erosions through defective epithelial attachment. This narrative review focuses on RCES associated with EBMD. It emphasizes how treatment choice depends on clinical findings, on whether the main goal is pain control, recurrence prevention, or visual rehabilitation, and on how directly the evidence applies to EBMD rather than to mixed-cause erosions. Lubrication and bandage lenses protect the healing surface, while anti-inflammatory and blood-derived therapies support repair. Debridement removes unstable epithelium; manual superficial keratectomy, diamond burr polishing, alcohol delamination, and phototherapeutic keratectomy treat the abnormal interface. Anterior stromal puncture provides focal scar-mediated anchoring, principally outside the visual axis. Contemporary procedural studies support individualized treatment but do not establish a universally superior technique. A heparan sulfate mimetic polymer has been tested directly in EBMD, but only in one small uncontrolled series; topical insulin, neurotrophic treatments, and differentiation-related targets lack EBMD-specific evidence of benefit. Epithelial closure, prevention of painful erosions, and optical rehabilitation are distinct outcomes and should not be treated as interchangeable measures of success. Management of EBMD-associated RCES should therefore be guided by the dominant clinical problem, lesion location, and the specific therapeutic outcome sought.

  • From earlier to updated quadrifocal intraocular lens designs: objective optical metrology analysis

    by Eun Ah Jeong, Seung Pil Bang, Seth Pantanelli, Sujin Kang, Sonia H. Yoo

    Purpose: To compare the optical performance of the Clareon PanOptix and Clareon PanOptix Pro intraocular lenses (IOLs) using interferometric metrology and identify measurable optical differences. Setting: Physiological Optics Laboratory, Daegu, South Korea. Design: Experimental optical-bench investigation. Methods: 3 +20.0-diopter samples each of the PanOptix and PanOptix Pro IOLs were analyzed using a Mach-Zehnder interferometer in a model eye incorporating +0.27 μm corneal spherical aberration (SA). Microscopic imaging, wavefront reconstruction with Zernike analysis, diffractive-step profile reconstruction, point-spread function (PSF)-based retinal image simulation, halo analysis, and through-focus modulation transfer function (MTF) analysis were performed. Results: Both IOLs showed broadly similar diffractive architecture and SA profiles. Peak-to-valley step-profile amplitudes were comparable, although the PanOptix Pro showed localized differences in the reconstructed step-height contour. PSF-based analyses showed broadly similar focal behavior, but the PanOptix Pro demonstrated clearer Sloan F contour preservation and more evident central PSF-core brightness at the far-intermediate position. In through-focus average MTF (aMTF) profiles, the PanOptix Pro showed a modestly higher far-focus peak and a less pronounced post-peak dip, particularly at 4.5 and 3.0 mm pupils. MTF50 analysis showed a similar overall pattern, with greater variability and more apparent intermodel differences at larger pupil sizes. Conclusions: The PanOptix Pro preserves the fundamental design and SA profile of the original PanOptix while showing localized diffractive step-height modifications. Together with clearer far-intermediate F-image preservation, sustained central PSF-core brightness, and a shallower post-peak aMTF dip, these findings are consistent with a relative redistribution of optical energy toward the far-intermediate region, supporting greater far-intermediate optical continuity without substantial changes in nominal add power or overall focal structure.

  • Open Access

    Intraocular Lens-Associated Uveitis-Glaucoma-Hyphema Syndrome

    by Sujin Kang, Despoina Theotoka, Dena Ballouz, Justin A. Chen, Angela Y. Zhu, William E. Smiddy, Steven J. Gedde, Elena Bitrian, Justin H. Townsend, Harry W. Flynn, et al.

  • Open Access

    Genetic Testing in Inherited Retinal Disease: Current Strategies and Future Directions

    by Sujin Kang, Byron L. Lam, Winston Lee, Audina M. Berrocal, Ninel Z. Gregori, Carlos E. Mendoza-Santiesteban, Jesse D. Sengillo

    Inherited retinal diseases (IRDs) are a major cause of visual impairment worldwide, marked by extensive genetic and phenotypic heterogeneity. Recent estimates from the U.S. suggest a prevalence of nearly 1 in 1000 individuals, reflecting both disease burden and improved diagnostic recognition. This review traces the shift from linkage analysis and Sanger sequencing to high-throughput next-generation sequencing, including panel-based, whole-exome, and whole-genome sequencing. Phenotype-driven testing strategies and standardized variant interpretation frameworks, such as the American College of Medical Genetics and Genomics guidelines, have substantially increased diagnostic yield. Copy number and structural variant detection, transcriptomics, and functional assays further help address unresolved cases. Nonetheless, barriers remain regarding cost, access, and the interpretation of variants of uncertain significance. Molecular confirmation has become essential for access to novel gene-directed therapies, exemplified by voretigene neparvovec for biallelic RPE65 variants, and is often a prerequisite for clinical trial participation. The growing role of genetic testing highlights the need for multidisciplinary evaluation and standardized outcome measures. Emerging tools, including artificial intelligence-assisted variant prioritization, image-to-genotype modeling, and multi-omics analyses, bridge molecular diagnoses with clinical phenotypes, accelerating the transition to targeted therapies. Continued progress will depend on increased access, standardized analytical regulations, and the integration of emerging technologies into routine clinical care.


  • Open Access

    Culture-proven endogenous endophthalmitis: ocular and systemic clinical features and outcomes

    by Charles Zhang, Mariam Tadross, Sujin Kang, Nicolas A. Yannuzzi, Thomas A. Albini, Harry W. Flynn

    Purpose: To report the clinical presentation, systemic associations, microbiologic spectrum, management strategies, and treatment outcomes of patients with culture-proven endogenous endophthalmitis. Methods: A retrospective review of medical records was conducted of patients with culture-proven endogenous endophthalmitis between 2013 and 2024. Data collected included demographics, systemic and ocular findings, culture results, imaging studies, management strategies, and treatment outcomes. Results: A total of 50 eyes from 41 patients were identified. Of these, 30/41 (73%) presented in an outpatient setting. The most common presenting symptom was blurred vision in 36/41 (88%) with only 16/41 (39%) presenting with systemic symptoms. Vitreous cultures disclosed fungal organisms in 19/41 (46%) of cases and bacterial in the remainder. Blood cultures were positive in 23/41 (56%). A systemic source of infection was identified in 23/41 (56%), most often associated with indwelling medical devices in 7/23 (30%). Intravenous drug use was present in 7/41 (17%). All patients received intravitreal antimicrobials and 25/50 (50%) underwent vitrectomy. Death associated with systemic infection occurred in only 3/41 (7%) of patients. Evisceration was performed in 2/50 (4%) eyes. Visual acuity at last follow up was ≥ 20/400 in 26/50 (52%) of eyes. Conclusions: Endogenous endophthalmitis was associated with a fungal source in 46% of cases and was not associated with systemic symptoms in 61% of cases. In the current study, indwelling medical devices remain an important source of infection. Despite prompt treatment, visual outcomes were generally poor.

  • Open Access

    Trends in Patient-Surgeon Sex Concordance and Surgical Volume in Cataract Surgery: A 14-Year Retrospective Cohort Study

    by Sujin Kang, Jerry Hsu, Ellen H. Koo, Kendall E. Donaldson, William W. Culbertson, Guillermo Amescua, Florence Cabot, Anat Galor, Sonia H. Yoo


  • Open Access

    Endogenous Versus Exogenous Candida Endophthalmitis: Clinical Features, Risk Factors, Treatment Modalities, and Visual Outcomes

    by Sujin Kang, Thomas A. Albini, Nicolas A. Yannuzzi, Sonia H. Yoo, Darlene Miller, Harry W. Flynn